Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide.
Aardvark Therapeutics
1 follower
Solace
2 followers
Transcure
2 followers
Merck
349 followers
American Academy of Family Physicians
1 follower
Unwell
1 follower
Latigo Biotherapeutics
1 follower
Karoo Health
1 follower
Yale New Haven Health System
3 followers
Revvity
15 followers
Health Career Connection
1 follower
UC Health
6 followers